GSA CONTRACT #: GS-35F-0448WTITLE: "CANCER MOONSHOT BIOBANK ONLINE CATALOG."NON-SEVERABLE (BASE PERIOD) / T&M TYPE BPA CALL.BPA CALL BASE PERIOD OF

总务管理局合同

• 批准号: 10282874
• 负责人: KEVIN MEAGHER
• 金额: $ 58.2万
• 依托单位: INFORMATION MANAGEMENT SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-27 至 2022-07-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10282874
• 关键词: Address; Area; Biological Assay; Cancer Patient; Catalogs; Clinical; Clinical Data; Collection; Communities; Community Hospitals; Consent; Contracts; Data; Databases; Elements; Enrollment; Ensure; Equipment and supply inventories; Goals; Informed Consent; Institution; Malignant Neoplasms; Medical; Molecular; National Cancer Institute; Participant; Pathology; Patients; Physicians; Policies; Population; Provider; Quality Control; Recommendation; Research; Research Personnel; Resources; Scientist; Site; Source; Specimen; System; Work; anticancer research; base; biobank; eligible participant; ethical legal social implication; programs; standard of care; tumor; user-friendly; web site

The National Cancer Institute’s (NCI) Cancer Moonshot Program is intended to accelerate cancer research in key strategic areas that were identified through a “Blue Ribbon Panel” (BRP) of experts. Core elements of the BRP recommendations include accelerating progress in cancer research by addressing critical scientific questions. Also included is the need for nationwide participation in research by patients that represent the diversity of the U.S. population. NCI has initiated the Cancer Moonshot Biobank to accelerate research through the collection and distribution of biospecimens for key research efforts. The Biobank will engage with over one thousand cancer patients, being treated with standard-of-care therapies, for longitudinal biospecimen collection. In keeping with the BRP recommendations, the cancer patients will be enrolled into the study from a diverse participant population engaged at medical institutions throughout the U.S. The biospecimens will be distributed to qualified scientists to accelerate research progress. The Biobank program, working closely with Leidos Biomedical, Inc. (LBR), will partner with community hospitals and other medical institutions, designated as Biospecimen Source Sites (BSS), to engage and consent eligible participants and collect biospecimens and associated clinical data; work with a central Biospecimen Core Resource (BCR) to support biospecimen collection, processing and storage activities and perform pathology quality control; work with LBR’s Molecular Characterization (MoCha) lab to perform clinical tumor molecular characterization assays and return results to patients and their physicians; and make the biospecimens and associated data available through an online catalog system to researchers to accelerate cancer research progress. Return of clinical results, a dedicated Patient and Provider Engagement (PPE) website, electronic informed consent, local participant engagement projects, and an embedded ethical, legal and social issues sub-study will together support patient and provider engagement in the program.

美国国家癌症研究所（NCI）的癌症登月计划旨在加速通过“蓝带小组”（BRP）专家确定的关键战略领域的癌症研究。BRP建议的核心要素包括通过解决关键的科学问题来加速癌症研究的进展。此外，还需要代表美国人口多样性的患者在全国范围内参与研究。NCI启动了癌症登月生物库，通过收集和分发生物标本来加速研究工作。生物库将与超过一千名接受标准治疗的癌症患者进行合作，以进行纵向生物标本收集。为了与BRP的建议保持一致，癌症患者将从美国各地医疗机构的不同参与者人群中招募到研究中，生物标本将分发给合格的科学家，以加速研究进展。生物库计划与Leidos Biomedical，Inc.密切合作。(LBR)，将与社区医院和其他医疗机构合作，指定为生物标本来源研究中心（BSS），以吸引并同意合格的参与者，并收集生物标本和相关临床数据;与中央生物标本核心资源（BCR）合作，以支持生物标本收集、处理和储存活动，并进行病理学质量控制;与LBR的分子表征（MoCha）实验室合作，进行临床肿瘤分子表征分析，并将结果返回给患者及其医生;并通过在线目录系统向研究人员提供生物样本和相关数据，以加速癌症研究进展。临床结果的返回、专用的患者和提供者参与（PPE）网站、电子知情同意书、当地参与者参与项目以及嵌入式伦理、法律的和社会问题子研究将共同支持患者和提供者参与该计划。